source
- GSK axes key cough drug candidate after phase 3 data end blockbuster hopesGSK has ended development of camlipixant in chronic cough after delivering mixed phase 3 data, dealing a major blow to a potential blockbuster that analysts saw as the key 2026 catalyst for the dru…Fierce Biotech · 12d ago↗ source
- Dimerix snaps up Mission’s stalled, phase 2-ready kidney disease candidate in $292M dealDimerix has bought an acute kidney injury drug from Mission Therapeutics, paying $5 million upfront and committing up to $287 million in milestones for the phase 2-ready asset.Fierce Biotech · 13d ago↗ source
- Biotronik Neuro snaps up spinal cord stimulation portfolio from Soin Neuroscience for next-gen pain projectBiotronik Neuro has acquired a portfolio of spinal cord stimulation patents from the Ohio-based medical device company Soin Neuroscience as the pair look to create “a next-generation spinal cord st…